



COPY OF PAPERS
ORIGINALLY FILED

PATENT
600-1-200NCIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: YONGWON CHOI *ET AL.*
SERIAL NO.: 09/873.829 EXAMINER: UNKNOWN
FILED: June 4, 2001 ART UNIT: 1646
FOR: A PROTEIN BELONGING TO THE TNF SUPERFAMILY
INVOLVED IN SIGNAL TRANSDUCTION, NUCLEIC ACIDS
ENCODING SAME, AND METHODS OF USE THEREOF

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on April 29, 2002.

Michael A. Yamin, Reg. No. 44,414
(Name of Registered Rep.)

Michael A. Yamin 4/29/02
(Signature and Date)

DECLARATION under 37 CFR 1.132

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

I, MICHAEL A. YAMIN, hereby declare and state that:

1. I am a Patent Agent and employed by the firm representing the Applicant in the above-identified Patent Application, Klauber and Jackson, where I have been employed since 1997.
2. In my capacity as Patent Agent for the firm, I prepared and assisted in the copying of documents for filing with the U.S. Patent and Trademark Office on June 4, 2001 with respect to the instant Application now designated U.S.S.N. 09/873,829.
3. Documents for filing were prepared, reviewed and executed by me and copies of the prior application, including the Specification, Declaration, and Drawings were made. At least two copies of each of the Specification, Declaration and Drawings of prior application

RECEIVED
JUL 24 2002
OFFICE OF PETITIONS

U.S.S.N. 09/210,115 were made. One copy of the above was provided to the U.S.P.T.O. for filing. The second copy was filed by myself as our file copy of the instant Application now assigned U.S.S.N. 09/873,829.

4. I have reviewed the firm's file copy of the instant Application U.S.S.N. 09/873,829, and I find that page 119 is present in the file copy. The attached copy of page 119 was made from the file copy of U.S.S.N. 09/873,829.

5. I hereby submit that the above facts, to the best of my knowledge and belief, are true. These facts demonstrate that, to the best of my knowledge and belief, the instant Application, when mailed to the U.S.P.T.O. on June 4, 2001 contained page 119.

6. I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further, that the statements are made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment or both under - §10001 of Title 18 of the United States code and that such wilful false statements may jeopardize the validity of the Application for any patent issuing thereon.



MICHAEL A. YAMIN
Agent for Applicants
Reg. No. 44,414

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601

Dated: 4/29/02

5 and

6 b) administering to the mammal a therapeutically effective amount of a
7 TRANCE agonist pharmaceutical composition of Claim 27

1 30 The method for treating an immune system related condition as set forth in
2 Claim 29, wherein said antigen is selected from the group consisting of:

- 3 a) a pathogen, or a fragment thereof;
4 b) a virus, or a fragment thereof; and
5 c) a tumor, or a fragment thereof.

1 31. The method for treating an immune system related condition as set forth in
2 Claim 29, wherein the immune system related condition is HIV or cancer.

1 32. The method for treating an immune system related condition as set forth in
2 Claim 29, wherein said pharmaceutically composition is administered orally,
3 pulmonarily, or nasally.

1 33. The method for treating an immune system related condition as set forth in
2 Claim 29, further comprising the steps of removing the at least one mature
3 dendritic cell from the mammal prior to the exposing step, and
4 reintroducing the mature dendritic cell into the mammal after the exposing
5 step, and prior to the administering step.

1 34. The method for treating an immune system related condition as set forth in
2 Claim 33, wherein the antigen is selected from the group consisting of:
3 a) a pathogen, or a fragment thereof,
4 b) a virus, or a fragment thereof, and
5 c) a tumor, or a fragment thereof

1 35. The method for treating an immune system related condition as set forth in
2 Claim 33, wherein the immune system related condition is HIV or cancer.